Clinical Trial Update: A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) [Phase 3]

View source ↗

Summary

Phase 3 study comparing adjuvant pembrolizumab plus vibostolimab (MK-7684A) versus pembrolizumab alone in patients with resected high-risk melanoma; the trial h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Vibostolimab (vibostolimab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2025-04-06